Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer

Nolasco‑Quiroga,Manuel; Rosas‑Díaz,Marisol; Moreno,José; Godínez‑Aguilar,Ricardo; López‑Ibarra,María   José; Piña‑Sánchez,Patricia; Alvarado‑Cabrero,Isabel; Vázquez‑Gómez,Gerardo; Rocha‑Zavaleta,Leticia; Arenas‑Aranda,Diego; Salamanca‑Gómez,Fabio

doi:10.3892/ol.2019.10147

Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer

Authors:
- Manuel Nolasco‑Quiroga
- Marisol Rosas‑Díaz
- José Moreno
- Ricardo Godínez‑Aguilar
- María José López‑Ibarra
- Patricia Piña‑Sánchez
- Isabel Alvarado‑Cabrero
- Gerardo Vázquez‑Gómez
- Leticia Rocha‑Zavaleta
- Diego Arenas‑Aranda
- Fabio Salamanca‑Gómez
View Affiliations

Affiliations: Laboratory of Molecular Genetics, Medical Research Unit, Mexican Social Security Institute, National Medical Center Century XXI, Hospital of Pediatrics, Mexico City 06720, Mexico, Multidisciplinary Academic Unit Reynosa‑Aztlan Reynosa, Autonomous University of Tamaulipas, Tamaulipas 88740, Mexico, Direction of Research, Hospital Juárez de México, Mexico City 07760, Mexico, Medical Research Unit of Oncologic Diseases, Oncology Hospital, Mexico City 06720, Mexico, Department of Anatomy‑Pathology, Mexican Social Security Institute, National Medical Center Century XXI, Oncology Hospital, Mexico City 06720, Mexico, Department of Genomic Medicine and Envornmental Toxicology, National University of Mexico, Mexico City 04510, Mexico, Department of Molecular Biology and Biotechnology, National University of Mexico, Mexico City 04510, Mexico
Published online on: March 15, 2019 https://doi.org/10.3892/ol.2019.10147
Pages: 4779-4786
Copyright: © Nolasco‑Quiroga et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Focal adhesion kinase (FAK) is a non‑receptor tyrosine kinase that is expressed in most human cell types (example: Epithelial cells, fibroblasts and endothelial), it serves a key role in the control of cell survival, proliferation and motility. The abnormal expression of FAK has been associated with poor prognosis in cancer, including ovarian cancer. However, although FAK isoforms with specific molecular and functional properties have been characterized, there are a limited number of published studies that examine FAK isoforms in ovarian cancer. The aim of the present study was to analyze the expression level of FAK and its isoforms in ovarian cancer. The expression of FAK kinase and focal adhesion targeting (FAT) domains was determined with immunohistochemistry in healthy ovary, and serous and mucinous cystadenoma, borderline tumor and carcinoma samples. Additionally, the expression of FAK and its isoforms were investigated in three ovarian cancer‑derived cell lines with western blotting and reverse transcription‑semi‑quantitative polymerase chain reaction. An increased expression of FAK kinase domain was determined in serous tumor samples and was associated with advancement of the lesion. FAK kinase domain expression was moderate‑to‑low in mucinous tumor samples. The expression of the FAK FAT domain in tumor samples was reduced, compared with healthy ovary samples; however, the FAT domain was localized to the cellular nucleus. Expression of alternative transcripts FAK0, FAK28,6 and FAK28 was determined in all three cell lines investigated. In conclusion, FAK kinase and FAT domains are differentially expressed among ovarian tumor types. These results indicated the presence of at least two isoforms of FAK (FAK and the putative FAK‑related non‑kinase) in tumor tissue, which is supported by the cells producing at least three FAK alternative transcripts. These results may support the use of FAK and its isoforms as biomarkers for ovarian cancer.

View Figures

View References

1	Coward JI, Middleton K and Murphy F: New perspectives on targeted therapy in ovarian cancer. Int J Womens Health. 7:189–203. 2015. View Article : Google Scholar : PubMed/NCBI
2	Iyoke CA and Ugwu GO: Burden of gynaecological cancers in developing countries. World J Obstet Gynecol. 2:1–7. 2013. View Article : Google Scholar
3	Rauh-Hain JA, Krivak TC, Del Carmen MG and Olawaiye AB: Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 4:15–21. 2011.PubMed/NCBI
4	Goff B: Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 55:36–42. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T and Nakano H: Histological classification of ovarian cancer. Med Electron Microsc. 36:9–17. 2003. View Article : Google Scholar : PubMed/NCBI
6	Leong HS, Galletta L, Etemadmoghadam D, George J; Australian Ovarian Cancer Study, ; Köbel M, Ramus SJ and Bowtell D: Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol. 236:272–277. 2015. View Article : Google Scholar : PubMed/NCBI
7	Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al: Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
8	Canney PA, Moore M, Wilkinson PM and James RD: Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer. 50:765–769. 1984. View Article : Google Scholar : PubMed/NCBI
9	Pepin K, Carmen MD, Brown A and Dizon DS: CA 125 and epithelial ovarian cancer: Role in screening, diagnosis, and surveillance. Am J Hematol Oncol. 10:22–29. 2014.
10	Mitra SK and Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 18:516–523. 2006. View Article : Google Scholar : PubMed/NCBI
11	Judson PL, He X, Cance WG and Van Le L: Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer. 86:1551–1556. 1999. View Article : Google Scholar : PubMed/NCBI
12	Li M, Hong LI, Liao M and Guo G: Expression and clinical significance of focal adhesion kinase and adrenomedullin in epithelial ovarian cancer. Oncol Lett. 10:1003–1007. 2015. View Article : Google Scholar : PubMed/NCBI
13	Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD and Hendrix MJ: Biological significance of focal adhesion kinase in ovarian cancer: Role in migration and invasion. Am J Pathol. 165:1087–1095. 2004. View Article : Google Scholar : PubMed/NCBI
14	Zhao X and Guan JL: Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 63:610–615. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hall JE, Fu W and Schaller MD: Focal adhesion kinase: Exploring Fak structure to gain insight into function. Int Rev Cell Mol Biol. 288:185–225. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lim ST: Nuclear FAK: A new mode of gene regulation from cellular adhesions. Mol Cells. 36:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
17	Dixon RD, Chen Y, Ding F, Khare SD, Prutzman KC, Schaller MD, Campbell SL and Dokholyan NV: New insights into FAK signaling and localization based on detection of a FAT domain folding intermediate. Structure. 12:2161–2171. 2004. View Article : Google Scholar : PubMed/NCBI
18	Schaller MD, Borgman CA and Parsons JT: Autonomous expression of a noncatalytic domain of the focal adhesion-associated protein tyrosine kinase pp125FAK. Mol Cell Biol. 13:785–791. 1993. View Article : Google Scholar : PubMed/NCBI
19	Toutant M, Costa A, Studler J, Kadaré G, Carnaud M and Girault JA: Alternative splicing controls the mechanisms of FAK autophosphorylation. Mol Cell Biol. 22:7731–7743. 2002. View Article : Google Scholar : PubMed/NCBI
20	Contestabile A, Bonanomi D, Burgaya F, Girault JA and Valtorta F: Localization of focal adhesion kinase isoforms in cells of the central nervous system. Int J Dev Neurosci. 21:83–93. 2003. View Article : Google Scholar : PubMed/NCBI
21	Corsi JM, Rouer E, Girault JA and Enslen H: Organization and post-transcriptional processing of focal adhesion kinase gene. BMC Genomics. 7:1982006. View Article : Google Scholar : PubMed/NCBI
22	Despeaux M, Chicanne G, Rouer E, De Toni-Costes F, Bertrand J, Mansat-De Mas V, Vergnolle N, Eaves C, Payrastre B, Girault JA and Racaud-Sultan C: Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling. Stem Cells. 30:1597–1610. 2012. View Article : Google Scholar : PubMed/NCBI
23	Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U and Bar-Shavit R: Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer. 113:372–378. 2005. View Article : Google Scholar : PubMed/NCBI
24	Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ and Cance W: High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol. 18:1289–1294. 2005. View Article : Google Scholar : PubMed/NCBI
25	Hidalgo A, Piña P, Guerrero G, Lazos M and Salcedo M: A simple method for the construction of small format tissue arrays. J Clin Pathol. 56:144–146. 2003. View Article : Google Scholar : PubMed/NCBI
26	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
27	Fogh J: Human tumor cells in vitro. Plenum Press; New York: pp. 115–141. 1975
28	Hamilton TC, Young RC, Mckoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR and Ozols RF: Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43:5379–5389. 1983.PubMed/NCBI
29	Provencher DM, Lounis H, Champoux L, Tétrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN and Mes-Masson AM: Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim. 36:357–361. 2000. View Article : Google Scholar : PubMed/NCBI
30	McCormack SJ, Brazinski SE, Moore JL Jr, Werness BA and Goldstein DJ: Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene. 15:265–274. 1997. View Article : Google Scholar : PubMed/NCBI
31	Pizon M, Schott DS, Pachmann U and Pachmann K: B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients. Int J Oncol. 53:2289–2299. 2018.PubMed/NCBI
32	Xu LH, Yang X, Craven RJ and Cance WG: The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ. 9:999–1005. 1998.PubMed/NCBI
33	Parsons JT: Focal adhesion kinase: The first ten years. J Cell Sci. 116:1409–1416. 2003. View Article : Google Scholar : PubMed/NCBI
34	Albasri A, Fadhil W, Scholefield JH, Durrant LG and Ilyas M: Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer. Anticancer Res. 34:3969–3974. 2014.PubMed/NCBI
35	Toutant M, Studler JM, Burgaya F, Costa A, Ezan P, Gelman M and Girault JA: Autophosphorylation of Tyr397 and its phosphorylation by Src-family kinases are altered in focal-adhesion-kinase neuronal isoforms. Biochem J. 348:119–128. 2000. View Article : Google Scholar : PubMed/NCBI